ABSTRACT
Introduction: the laboratory diagnosis of meningococcal meningitis relies on conventional techniques. This study aims to evaluate the correlation between the reduced sensitivity to penicillin G of Neisseria meningitidis (N.m) strains and the expression of the altered PBP 2 gene. Methods: out of 190 strains of N.m isolated between 2010 and 2021 at the bacteriology laboratories of Ibn Rochd University Hospital Centre (IR-UHC) in Casablanca and the UHC Mohammed VI in Marrakech, 23 isolates were part of our study. We first determined their state of sensitivity to penicillin G by E-Test strips and searched for the expression of the penA gene by PCR followed by Sanger sequencing. Results: of all the confirmed cases of N.m, 93.15% (n=177) are of serogroup B, 75.2% (n = 143) are sensitive to penicillin G and 24.73% (n = 47) are of intermediate sensitivity. No resistance to penicillin G was observed. Reduced sensitivity to penicillin G in N.m is characterized by mutations namely F504 L, A510 V, I515 V, G541 N and I566 V located in the C-terminal region of the penA gene encoding the penicillin-binding protein 2 (PBP2) (mosaic gene). Conclusion: our study presents useful data for the phenotypic and genotypic monitoring of resistance to penicillin G in N.m and can contribute to the analysis of genetic exchanges between different Neisseria species.
Subject(s)
Anti-Bacterial Agents , Hospitals, University , Meningitis, Meningococcal , Microbial Sensitivity Tests , Neisseria meningitidis , Penicillin G , Morocco , Humans , Anti-Bacterial Agents/pharmacology , Neisseria meningitidis/genetics , Neisseria meningitidis/drug effects , Neisseria meningitidis/isolation & purification , Penicillin G/pharmacology , Meningitis, Meningococcal/microbiology , Meningitis, Meningococcal/drug therapy , Polymerase Chain Reaction , Mutation , Penicillin-Binding Proteins/genetics , Bacterial Proteins/genetics , Penicillin Resistance/genetics , Drug Resistance, Bacterial/genetics , Neisseria meningitidis, Serogroup B/genetics , Neisseria meningitidis, Serogroup B/isolation & purification , Neisseria meningitidis, Serogroup B/drug effectsABSTRACT
PURPOSE: The purpose of this study was to assess the clinical outcomes of adults with invasive meningococcal disease (IMD) and to compare the outcomes of patients with IMD caused by a penicillin susceptible isolate (minimum inhibitory concentration (MIC) ≤ 0.06 mg/L) with patients with IMD caused by an isolate with reduced penicillin susceptibility (MIC > 0.06 mg/L). We also assessed the outcomes of patients with IMD caused by an isolate with reduced penicillin susceptibility who were treated exclusively with intravenous (IV) benzylpenicillin. METHODS: Retrospective study of all culture positive IMD in adult patients (age ≥ 15 years) in the Auckland region from 2004 to 2017. RESULTS: One hundred and thirty-nine patients were included; 94 had penicillin susceptible isolates (88 cured, 6 died), and 45 had an isolate with reduced penicillin susceptibility (41 cured, 1 possible relapse, 3 died). The median benzylpenicillin/ceftriaxone treatment duration was 3 days for both groups. There was no difference in the patient outcomes of both groups. Eighteen patients with IMD caused by an isolate with reduced penicillin susceptibility received benzylpenicillin alone and were cured. CONCLUSIONS: This study provides further support to existing data that has shown that short duration IV beta-lactam treatment is effective for IMD in adults. Only a small number of patients with meningitis caused by an isolate with reduced penicillin susceptibility received benzylpenicillin alone, limiting its evaluation. For Neisseria meningitidis meningitis, we recommend ceftriaxone as empiric treatment and as definitive treatment when this is caused by an isolate with reduced penicillin susceptibility.
Subject(s)
Meningitis, Meningococcal , Meningococcal Infections , Neisseria meningitidis , Adult , Humans , Adolescent , Penicillins/pharmacology , Penicillins/therapeutic use , Ceftriaxone/therapeutic use , Retrospective Studies , Meningococcal Infections/drug therapy , Meningococcal Infections/epidemiology , Penicillin G/pharmacology , Penicillin G/therapeutic use , Microbial Sensitivity Tests , Meningitis, Meningococcal/drug therapyABSTRACT
Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, can have a fatality rate as high as 10%, even with appropriate treatment. In the UK, penicillin is administered to patients in primary care whilst third generation cephalosporins, cefotaxime and ceftriaxone, are administered in secondary care. The first-choice antibiotic for chemoprophylaxis of close contacts is ciprofloxacin, followed by rifampicin. Immunocompromised individuals are often recommended antibiotic chemoprophylaxis and vaccination due to a greater risk of IMD. Resistance to antibiotics among meningococci is relatively rare, however reduced susceptibility and resistance to penicillin are increasing globally. Resistance to third generation cephalosporins is seldom reported, however reduced susceptibility to both cefotaxime and ceftriaxone has been observed. Rifampicin resistance has been reported among meningococci, mainly following prophylaxis, and ciprofloxacin resistance, whilst uncommon, has also been reported across the globe. The Public Health England Meningococcal Reference Unit receives and characterises the majority of isolates from IMD cases in England, Wales and Northern Ireland. This study assessed the distribution of antibiotic resistance to penicillin, rifampicin, ciprofloxacin and cefotaxime among IMD isolates received at the MRU from 2010/11 to 2018/19 (n = 4,122). Out of the 4,122 IMD isolates, 113 were penicillin-resistant, five were ciprofloxacin-resistant, two were rifampicin-resistant, and one was cefotaxime-resistant. Penicillin resistance was due to altered penA alleles whilst rifampicin and ciprofloxacin resistance was due to altered rpoB and gyrA alleles, respectively. Cefotaxime resistance was observed in one isolate which had an altered penA allele containing additional mutations to those harboured by the penicillin-resistant isolates. This study identified several isolates with resistance to antibiotics used for current treatment and prophylaxis of IMD and highlights the need for continued surveillance of resistance among meningococci to ensure continued effective use.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Microbial , Meningitis, Meningococcal/drug therapy , Neisseria meningitidis/drug effects , Anti-Bacterial Agents/pharmacology , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , England/epidemiology , Humans , Meningitis, Meningococcal/epidemiology , Neisseria meningitidis/isolation & purification , Northern Ireland/epidemiology , Penicillins/pharmacology , Penicillins/therapeutic use , Rifampin/pharmacology , Rifampin/therapeutic use , Wales/epidemiologyABSTRACT
Neisseria meningtidis is responsible for causing meningococcal meningitis along with acute septicaemia in human beings. Functional genomics strategies proved cruciality of certain genes/proteins in Neisseria meningitidis pathogenesis. During the present studies, three important Neisseria meningitidis proteins i.e., Dead box RNA-Helicase, Polyribonucleotide nucleotidyl-transferase PNPase and Ribonuclease-III were targeted for homology modeling and protein-ligand docking studies not only to determine their three dimensional architectures but also to identify their potential novel inhibitors. The Biscoumarin, malonitrile and indole derivatives showed the best inhibitory mode against all of the three enzymes. Since, these enzymes are assembled in Gram-negative bacteria to form RNA degradosome assembly therefore their inhibition will definitely shut off the degradosome assembly and ultimately the decay of RNA, which is an essential life process. This is the first ever structural investigation of these drug targets along with identification of potential novel drug candidates. We believe that these small chemical compounds will be proved as better drugs and will provide an excellent barrier towards Neisseria meningitidis pathogenesis.
Subject(s)
Anti-Bacterial Agents/chemistry , DEAD-box RNA Helicases/chemistry , DEAD-box RNA Helicases/genetics , Molecular Docking Simulation/methods , Neisseria meningitidis/chemistry , Neisseria meningitidis/genetics , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Humans , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/genetics , Neisseria meningitidis/drug effects , Protein Structure, SecondaryABSTRACT
Herpes simplex virus 2 (HSV-2) is a well-known cause of neurological complications. This case study describes the first reported case of reactivated HSV-2 myelitis, which was induced by immunosuppression due to sepsis. During the treatment of meningococcal meningitis, the patient developed quadriparesis and was later diagnosed as HSV-2 myelitis, mimicking ICU-acquired weakness. The case emphasizes the importance of excluding viral myelitis before making the diagnosis of ICU-acquired weakness.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Herpes Simplex/diagnostic imaging , Herpesvirus 2, Human/isolation & purification , Meningitis, Meningococcal/complications , Myelitis/diagnostic imaging , Quadriplegia/etiology , Ampicillin/therapeutic use , Herpes Simplex/etiology , Herpes Simplex/virology , Humans , Immunosuppression Therapy/adverse effects , Intensive Care Units , Male , Meningitis, Meningococcal/drug therapy , Middle Aged , Myelitis/etiology , Myelitis/virology , Virus ActivationABSTRACT
Bacterial co-infection in the ongoing pandemic of COVID-19 is associated with poor outcomes but remains little understood. A 22-year-old woman presented with a 3-week history of fever, headache, neck stiffness, rigours and confusion. She was noted to have a purpuric rash over her hands and feet. Cerebrospinal fluid bacterial PCR was positive for Neisseria meningitidis A concurrent nasopharyngeal RT-PCR was positive for SARS-CoV-2, the causative virus of COVID-19. She was treated with antibiotics for bacterial meningitis and made a complete recovery. Bacterial infection from nasopharyngeal organisms has followed previous pandemic viral upper respiratory illnesses and the risk of bacterial co-infection in COVID-19 remains unclear. Research characterising COVID-19 should specify the frequency, species and outcome of bacterial co-infection. Management of bacterial co-infection in COVID-19 presents major challenges for antimicrobial stewardship and clinical management. Judicious use of local antibiotic guidelines and early liaison with infection specialists is key.
Subject(s)
Coinfection , Coronavirus Infections/complications , Meningitis, Meningococcal/complications , Pneumonia, Viral/complications , Anti-Bacterial Agents/therapeutic use , Betacoronavirus , COVID-19 , Ceftriaxone/therapeutic use , Coronavirus Infections/diagnosis , Female , Humans , Meningitis, Meningococcal/drug therapy , Pandemics , Pneumonia, Viral/diagnosis , Risk Factors , SARS-CoV-2 , Young AdultABSTRACT
BACKGROUND: Meningococcal meningitis (MM) is a life-threatening disease associated with approximately 10% case fatality rates and neurological sequelae in 10-20% of the cases. Recently, we have shown that the matrix metalloproteinase (MMP) inhibitor BB-94 reduced brain injury in a mouse model of MM. The present study aimed to assess whether doxycycline (DOX), a tetracycline that showed a neuroprotective effect as adjuvant therapy in experimental pneumococcal meningitis (PM), would also exert a beneficial effect when given as adjunctive therapy to ceftriaxone (CRO) in experimental MM. METHODS: BALB/c mice were infected by the intracisternal route with a group C Neisseria meningitidis strain. Eighteen h post infection (hpi), animals were randomised for treatment with CRO [100 mg/kg subcutaneously (s.c.)], CRO plus DOX (30 mg/kg s.c.) or saline (control s.c.). Antibiotic treatment was repeated 24 and 40 hpi. Mouse survival and clinical signs, bacterial counts in cerebella, brain damage, MMP-9 and cyto/chemokine levels were assessed 48 hpi. RESULTS: Analysis of bacterial load in cerebella indicated that CRO and CRO + DOX were equally effective at controlling meningococcal replication. No differences in survival were observed between mice treated with CRO (94.4%) or CRO + DOX (95.5%), (p > 0.05). Treatment with CRO + DOX significantly diminished both the number of cerebral hemorrhages (p = 0.029) and the amount of MMP-9 in the brain (p = 0.046) compared to untreated controls, but not to CRO-treated animals (p > 0.05). Levels of inflammatory markers in the brain of mice that received CRO or CRO + DOX were not significantly different (p > 0.05). Overall, there were no significant differences in the parameters assessed between the groups treated with CRO alone or CRO + DOX. CONCLUSIONS: Treatment with CRO + DOX showed similar bactericidal activity to CRO in vivo, suggesting no antagonist effect of DOX on CRO. Combined therapy significantly improved mouse survival and disease severity compared to untreated animals, but addition of DOX to CRO did not offer significant benefits over CRO monotherapy. In contrast to experimental PM, DOX has no adjunctive activity in experimental MM.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Doxycycline/therapeutic use , Meningitis, Meningococcal/drug therapy , Neisseria meningitidis, Serogroup C , Animals , Anti-Bacterial Agents/administration & dosage , Bacterial Load/drug effects , Ceftriaxone/administration & dosage , Cerebral Hemorrhage/drug therapy , Chemokines/analysis , Chemokines/metabolism , Disease Models, Animal , Doxycycline/administration & dosage , Drug Therapy, Combination , Female , Humans , Kaplan-Meier Estimate , Matrix Metalloproteinase 9/analysis , Matrix Metalloproteinase 9/metabolism , Meningitis, Meningococcal/mortality , Mice , Mice, Inbred BALB C , Random Allocation , Treatment OutcomeABSTRACT
RATIONALE: Late complement deficiency increases susceptibility to meningococcal disease and recurrent infections. In Korea, 5 case reports have described meningococcal disease with complement deficiency. However, C6 deficiency has not been described previously. PATIENT CONCERNS: A 21-year-old police trainee presented with recurrent meningococcal meningitis. He was housed in communal living quarters until 20 days before the initial symptom onset. DIAGNOSIS: He was diagnosed with meningococcal meningitis with C6 deficiency. INTERVENTIONS: He was treated with intravenous ceftriaxone. An additional dose of quadrivalent meningococcal conjugate vaccine was administered after discharge. OUTCOMES: He was discharged without complications. LESSONS: Screening for complement deficiency is necessary in patients with a history of recurrent meningococcal infections to provide appropriate care and prevent recurrent infections.
Subject(s)
Complement C6/deficiency , Meningitis, Meningococcal/diagnosis , Complement C6/immunology , Exanthema/etiology , Fever/etiology , Headache/etiology , Humans , Male , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/immunology , Meningococcal Vaccines/standards , Meningococcal Vaccines/therapeutic use , Recurrence , Republic of Korea , Young AdultABSTRACT
Neisseria meningitidis (N. meningitidis) is regarded as the leading cause of bacterial meningitis in many regions of the world. The empiric antimicrobial treatment is mainly based on antimicrobial resistance and patient characteristics. We aimed to analyze susceptibility patterns of N. meningitidis strains isolated in Turkey. Invasive meningococci collected in a multicenter, hospital-based, epidemiological surveillance study of pediatric (0-18 years of age) bacterial meningitis cases between 2013 and 2018 were studied. Five isolates (8.7%) displayed resistance to penicillin-G, while 13 isolates (22.8%) had intermediate susceptibility. All isolates were cefotaxime and rifampin susceptible. The data shows appropriateness of third-generation cephalosporins in empirical use for meningococcal infections in children. Since Turkey is located in a transition zone geographically, surveillance reports are very crucial.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/epidemiology , Neisseria meningitidis/isolation & purification , Penicillin Resistance/drug effects , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Microbial Sensitivity Tests , Turkey/epidemiologyABSTRACT
BACKGROUND: RBx 14255 is a fluoroketolide in pre-clinical evaluation with potent activity against MDR Gram-positive pathogens. OBJECTIVES: To investigate the efficacy of RBx 14255 against bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis or Haemophilus influenzae in an experimental murine meningitis model. METHODS: In vitro activity of RBx 14255 was evaluated against clinical isolates of S. pneumoniae, N. meningitidis and H. influenzae. The in vivo efficacy of RBx 14255 was evaluated against bacterial meningitis, induced with S. pneumoniae 3579 erm(B), S. pneumoniae MA 80 erm(B), N. meningitidis 1852 and H. influenzae B1414 in a murine meningitis model. RESULTS: RBx 14255 showed strong in vitro bactericidal potential against S. pneumoniae, N. meningitidis and H. influenzae with MIC ranges of 0.004-0.1, 0.03-0.5 and 1-4 mg/L, respectively. In a murine meningitis model, a 50 mg/kg dose of RBx 14255, q12h, resulted in significant reduction of bacterial counts in the brain compared with the pretreatment control. The concentration of RBx 14255 in brain tissue correlated well with the efficacy in this mouse model. CONCLUSIONS: RBx 14255 showed superior bactericidal activity in time-kill assays in vitro and in vivo in an experimental murine meningitis model. RBx 14255 could be a promising candidate for future drug development against bacterial meningitis.
Subject(s)
Anti-Bacterial Agents/pharmacology , Haemophilus influenzae/drug effects , Ketolides/pharmacology , Neisseria meningitidis/drug effects , Streptococcus pneumoniae/drug effects , Animals , Anti-Bacterial Agents/chemistry , Disease Models, Animal , Haemophilus Infections/drug therapy , Haemophilus Infections/microbiology , Ketolides/chemistry , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/microbiology , Meningitis, Meningococcal/pathology , Mice , Microbial Sensitivity Tests , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/pathologyABSTRACT
The permeation of most antibiotics through the outer membrane of Gram-negative bacteria occurs through porin channels. To design drugs with increased activity against Gram-negative bacteria in the face of the antibiotic resistance crisis, the strict constraints on the physicochemical properties of the permeants imposed by these channels must be better understood. Here we show that a combination of high-resolution electrophysiology, new noise-filtering analysis protocols and atomistic biomolecular simulations reveals weak binding events between the ß-lactam antibiotic ampicillin and the porin PorB from the pathogenic bacterium Neisseria meningitidis. In particular, an asymmetry often seen in the electrophysiological characteristics of ligand-bound channels is utilised to characterise the binding site and molecular interactions in detail, based on the principles of electro-osmotic flow through the channel. Our results provide a rationale for the determinants that govern the binding and permeation of zwitterionic antibiotics in porin channels.
Subject(s)
Ampicillin/metabolism , Anti-Bacterial Agents/metabolism , Neisseria meningitidis/metabolism , Porins/metabolism , Ampicillin/pharmacokinetics , Anti-Bacterial Agents/pharmacokinetics , Humans , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/microbiology , Models, Molecular , Neisseria meningitidis/drug effects , Permeability , beta-Lactams/metabolism , beta-Lactams/pharmacokineticsABSTRACT
OBJECTIVES: To describe the cluster of MenC ST11 Invasive Meningococcal Disease (IMD) occurred in Tuscany in the years 2015-2016. METHODS: A retrospective charts analysis of clinical, epidemiological and microbiological aspects of documented IMD was performed. Prognostic factors for death were evaluated. RESULTS: Sixty-one patients with IMD in the 2015-2016 period were documented: 28 had meningococcemia, 24 meningitis plus meningococcemia and 9 meningitis. MenC ST11 (cc11) was identified in 48/54 (89%) of the tested strains. All patients, with the exception of three very early death, received timely and appropriate antibiotic therapy and, in selected case, adjunctive therapy with steroids and Pentaglobin®. Forty-one patients recovered (67.3%, mean age: 26â¯years), 7 had permanent sequelae (11.3%, mean age 31â¯years) and 13 died (21.3%; mean age: 46â¯years). In a multivariate analysis, septic shock, purpura fulminans and advanced age were negative prognostic factors, while emergency admittance to a tertiary-care, university hospital, positively influenced the survival rate. The epidemiological analysis of the cluster identified close contacts and recreational environments such as discos as hotspot for MenC transmission. After a massive vaccination campaign, the number of MenC cases reported in Tuscany in 2017 decreased to 10, with no death. CONCLUSIONS: Vaccination campaign of key populations together with the need for rapid and qualified emergency care of the affected patients seems to be the main lesson learned by the MenC ST11 Tuscany epidemic.
Subject(s)
Mass Vaccination , Meningitis, Meningococcal/epidemiology , Meningococcal Infections/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , Epidemics/prevention & control , Epidemics/statistics & numerical data , Female , Hospitalization , Humans , Incidence , Infant , Italy/epidemiology , Male , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/microbiology , Meningococcal Infections/drug therapy , Meningococcal Infections/mortality , Middle Aged , Neisseria meningitidis, Serogroup C , Retrospective Studies , Shock, Septic , Young AdultABSTRACT
BACKGROUND: Antibiotic prophylaxis for contacts of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal meningitis. METHODS AND FINDINGS: In this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care (the control arm), single-dose oral ciprofloxacin for household contacts within 24 hours of case notification, or village-wide distribution of ciprofloxacin within 72 hours of first case notification. The primary outcome was the overall AR of suspected meningitis after inclusion. A random sample of 20 participating villages was enrolled to document any changes in fecal carriage prevalence of ciprofloxacin-resistant and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae before and after the intervention. Between April 22 and May 18, 2017, 49 villages were included: 17 to the control arm, 17 to household prophylaxis, and 15 to village-wide prophylaxis. A total of 248 cases were notified in the study after the index cases. The AR was 451 per 100,000 persons in the control arm, 386 per 100,000 persons in the household prophylaxis arm (t test versus control p = 0.68), and 190 per 100,000 persons in the village-wide prophylaxis arm (t test versus control p = 0.032). The adjusted AR ratio between the household prophylaxis arm and the control arm was 0.94 (95% CI 0.52-1.73, p = 0.85), and the adjusted AR ratio between the village-wide prophylaxis arm and the control arm was 0.40 (95% CI 0.19â0.87, p = 0.022). No adverse events were notified. Baseline carriage prevalence of ciprofloxacin-resistant Enterobacteriaceae was 95% and of ESBL-producing Enterobacteriaceae was >90%, and did not change post-intervention. One limitation of the study was the small number of cerebrospinal fluid samples sent for confirmatory testing. CONCLUSIONS: Village-wide distribution of single-dose oral ciprofloxacin within 72 hours of case notification reduced overall meningitis AR. Distributions of ciprofloxacin could be an effective tool in future meningitis outbreak responses, but further studies investigating length of protection, effectiveness in urban settings, and potential impact on antimicrobial resistance patterns should be carried out. TRIAL REGISTRATION: ClinicalTrials.gov NCT02724046.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/statistics & numerical data , Ciprofloxacin/therapeutic use , Epidemics , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/epidemiology , Administration, Oral , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Male , Meningitis, Meningococcal/microbiology , Neisseria meningitidis/drug effects , Neisseria meningitidis/physiology , Niger/epidemiology , Young AdultABSTRACT
Although outbreaks of Neisseria meningitidis serogroup X occured in a couple of African countries, a limited number of serogroup X meningococcal cases were reported in America and Europe as well as Turkey. Additionally, serogroup X is still not represented in current conjugated meningococcal vaccines. Here, we describe the first pediatric case with meningitis caused by Neisseria meningitidis serogroup X ST-5799 (ST-22 complex) that formed a distinct lineage.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Meningitis, Meningococcal/microbiology , Neisseria meningitidis/immunology , Serogroup , DNA, Bacterial/cerebrospinal fluid , DNA, Bacterial/isolation & purification , Drug Therapy, Combination/methods , Humans , Infant , Male , Meningitis, Meningococcal/diagnosis , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/immunology , Neisseria meningitidis/genetics , Neisseria meningitidis/isolation & purification , Phylogeny , Treatment Outcome , TurkeyABSTRACT
BACKGROUND: We report the first adult case of Neisseria meningitidis W-135 presenting with meningococcal arthritis and myopericarditis concomitantly, without other classical features of meningococcal disease. CASE PRESENTATION: A 67-year-old Caucasian man presented with acute-onset polyarthralgia, myalgia, and fever. On examination he had polyarticular synovitis. An electrocardiogram (ECG) demonstrated ST-elevation in leads I, II, III, aVF, and V2-V6 without reciprocal depression, and a high-sensitivity troponin level was significantly elevated. Cardiac magnetic resonance (CMR) imaging on day five of admission demonstrated patchy pericardial enhancement. Neisseria meningitidis W-135 was isolated from both synovial fluid and blood cultures. The clinical outcome was favourable with intravenous ceftriaxone and myopericarditis treatment (colchicine and ibuprofen). CONCLUSIONS: We conclude that this is a rare case of disseminated Neisseria meningitidis W-135 presenting with acute polyarticular septic arthritis and myopericarditis, without other classical features of systemic meningococcal disease. The earlier described entity of primary meningococcal arthritis (PMA) can present in patients with meningococcal bacteraemia, and may not be distinct from disseminated meningococcal disease, but rather an atypical presentation of this.
Subject(s)
Arthritis, Infectious/diagnosis , Meningitis, Meningococcal/diagnosis , Myocarditis/diagnosis , Aged , Arthritis, Infectious/drug therapy , Arthritis, Infectious/microbiology , Blood Culture , Ceftriaxone/therapeutic use , Electrocardiography , Humans , Magnetic Resonance Imaging, Cine , Male , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/microbiology , Myocarditis/drug therapy , Myocarditis/microbiology , Neisseria meningitidis/isolation & purification , Synovial Fluid/microbiologySubject(s)
Meningitis, Meningococcal/epidemiology , Meningitis, Meningococcal/microbiology , Neisseria meningitidis, Serogroup C , Advisory Committees , Africa/epidemiology , Anti-Bacterial Agents/therapeutic use , Benin/epidemiology , Burkina Faso/epidemiology , Ciprofloxacin/therapeutic use , Epidemics , Humans , Mali/epidemiology , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/prevention & control , Niger/epidemiology , Nigeria/epidemiology , Population Surveillance , Risk , Vaccination , World Health OrganizationABSTRACT
PURPOSE: Prompt recognition and aggressive early treatment are the only effective measures against invasive meningococcal disease (IMD). Anti-inflammatory adjunctive treatment remains controversial and difficult to assess in patients with IMD. The purpose of this study was to evaluate the effect of dexamethasone (DXM) as adjunctive treatment in different clinical forms of IMD, and attempt to answer if DXM should be routinely used in the treatment of IMD. METHODS: In this non-interventional clinical study (NIS), 39 patients with meningococcal septicaemia with or without of meningitis were included, and compared regarding the impact of dexamethasone (DXM), as an adjunctive treatment, on the outcome of IMD. SPSS statistics is used for statistical processing of data. RESULTS: Thirty (76.9%) patients with IMD had sepsis and meningitis, and 9 (23.1%) of them had sepsis alone. Dexamethasone was used in 24 (61.5%) cases, in both clinical groups. The overall mortality rate was 10.3%. Pneumonia was diagnosed in 6 patients (15.4%), arthritis in 3 of them (7.7%), and subdural effusion in one patient (2.6%). The data showed a significant statistical difference on the length of hospitalization, and WBC normalization in groups of patients treated with DXM. CONCLUSION: The use of DXM as adjunctive therapy in invasive meningococcal disease has a degree of proven benefits and no harmful effects. In fighting this very dangerous and complex infection, even a limited benefit is sufficient to recommend the use of DXM as adjunctive treatment in invasive meningococcal disease.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Dexamethasone/therapeutic use , Meningitis, Meningococcal/drug therapy , Sepsis/drug therapy , Adolescent , Adult , Arthritis, Infectious/diagnosis , Chemotherapy, Adjuvant , Child , Child, Preschool , Female , Hospitalization , Humans , Infant , Infant, Newborn , Male , Pneumonia, Bacterial/diagnosis , Treatment Outcome , Young AdultABSTRACT
The pathogenic Neisseria provide textbook examples of phase variation: the high frequency, random and reversible switching of gene expression. Typically, phase variable gene expression is observed in genes required for the expression of surface proteins and carbohydrate structures. All Neisseria gonorrhoeae and N. meningitidis strains also express phase variable DNA methyltransferases that are components of DNA restriction-modification systems. Phase variation of these DNA methyltransferases (Mod) alters global DNA methylation patterns. The change in DNA methylation due to phase variation events alters expression of a regulon of genes, called a phasevarion, and results in differentiation of the population into cells with two distinct phenotypes. For example, in N. meningitidis switching of the modA11 phasevarion alters expression of immunogenic outer membrane proteins such as lactoferrin-binding protein, and also modulates sensitivity to ceftazidime and ciprofloxacin. The modD1 phasevarion is associated with hypervirulent meningococcal clonal complexes. In N. gonorrhoeae, modA13 phasevarion switching generates differentiation into cells that display enhanced biofilm formation and enhanced intracellular survival. Phasevarions are ubiquitous in pathogenic Neisseria and modulate expression of numerous genes. These systems have the potential to impact all studies on vaccine development and pathobiology in the pathogenic Neisseria.
Subject(s)
DNA Modification Methylases/genetics , Epigenesis, Genetic , Gene Expression Regulation, Bacterial , Neisseria gonorrhoeae/genetics , Neisseria meningitidis/genetics , Anti-Bacterial Agents/therapeutic use , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/immunology , Bacterial Outer Membrane Proteins/metabolism , Ceftazidime/therapeutic use , Ciprofloxacin/therapeutic use , DNA Methylation , DNA Modification Methylases/immunology , DNA Modification Methylases/metabolism , Gonorrhea/drug therapy , Gonorrhea/immunology , Gonorrhea/microbiology , Gonorrhea/pathology , Humans , Immune Evasion , Meningitis, Meningococcal/drug therapy , Meningitis, Meningococcal/immunology , Meningitis, Meningococcal/microbiology , Meningitis, Meningococcal/pathology , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/immunology , Neisseria gonorrhoeae/metabolism , Neisseria meningitidis/drug effects , Neisseria meningitidis/immunology , Neisseria meningitidis/metabolism , Receptors, Cell Surface/genetics , Receptors, Cell Surface/immunology , Receptors, Cell Surface/metabolism , RegulonABSTRACT
BACKGROUND: Meningococcal disease can lead to death or disability within hours after onset. Pre-admission antibiotics aim to reduce the risk of serious disease and death by preventing delays in starting therapy before confirmation of the diagnosis. OBJECTIVES: To study the effectiveness and safety of pre-admission antibiotics versus no pre-admission antibiotics or placebo, and different pre-admission antibiotic regimens in decreasing mortality, clinical failure, and morbidity in people suspected of meningococcal disease. SEARCH METHODS: We searched CENTRAL (6 January 2017), MEDLINE (1966 to 6 January 2017), Embase (1980 to 6 January 2017), Web of Science (1985 to 6 January 2017), LILACS (1982 to 6 January 2017), and prospective trial registries to January 2017. We previously searched CAB Abstracts from 1985 to June 2015, but did not update this search in January 2017. SELECTION CRITERIA: Randomised controlled trials (RCTs) or quasi-RCTs comparing antibiotics versus placebo or no intervention, in people with suspected meningococcal infection, or different antibiotics administered before admission to hospital or confirmation of the diagnosis. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data from the search results. We calculated the risk ratio (RR) and 95% confidence interval (CI) for dichotomous data. We included only one trial and so did not perform data synthesis. We assessed the overall quality of the evidence using the GRADE approach. MAIN RESULTS: We found no RCTs comparing pre-admission antibiotics versus no pre-admission antibiotics or placebo. We included one open-label, non-inferiority RCT with 510 participants, conducted during an epidemic in Niger, evaluating a single dose of intramuscular ceftriaxone versus a single dose of intramuscular long-acting (oily) chloramphenicol. Ceftriaxone was not inferior to chloramphenicol in reducing mortality (RR 1.21, 95% CI 0.57 to 2.56; N = 503; 308 confirmed meningococcal meningitis; 26 deaths; moderate-quality evidence), clinical failures (RR 0.83, 95% CI 0.32 to 2.15; N = 477; 18 clinical failures; moderate-quality evidence), or neurological sequelae (RR 1.29, 95% CI 0.63 to 2.62; N = 477; 29 with sequelae; low-quality evidence). No adverse effects of treatment were reported. Estimated treatment costs were similar. No data were available on disease burden due to sequelae. AUTHORS' CONCLUSIONS: We found no reliable evidence to support the use pre-admission antibiotics for suspected cases of non-severe meningococcal disease. Moderate-quality evidence from one RCT indicated that single intramuscular injections of ceftriaxone and long-acting chloramphenicol were equally effective, safe, and economical in reducing serious outcomes. The choice between these antibiotics should be based on affordability, availability, and patterns of antibiotic resistance.Further RCTs comparing different pre-admission antibiotics, accompanied by intensive supportive measures, are ethically justified in people with less severe illness, and are needed to provide reliable evidence in different clinical settings.